Nephrotoxicity of Immune Checkpoint Inhibitors in Mice with a Human Immune System

This study demonstrates that a human immune system tumor-bearing mouse model treated with nivolumab and ipilimumab reproducibly recapitulates human ICI-induced nephrotoxicity, revealing that renal injury is driven by CD4+ T-cell enrichment and specific immune protein shifts rather than traditional biomarkers, thereby validating this platform for mechanistic investigation and therapeutic testing.

The Gist

Imagine your body's immune system as a highly trained security team. Its job is to spot and destroy bad guys, like cancer cells. However, sometimes this team gets too aggressive and starts attacking innocent people, like your own healthy organs. This is what happens with a type of cancer drug called an Immune Checkpoint Inhibitor (ICI). These drugs are like removing the "brakes" from the security team so they can fight cancer harder, but sometimes that leads to accidental damage to the kidneys.

This paper is like a detective story where scientists tried to figure out exactly how and why these drugs hurt the kidneys, using a very special kind of mouse.

The Special "Human" Mouse

You can't just test these drugs on regular mice because their immune systems are too different from ours. So, the scientists created a "Frankenstein" mouse (a HIS-BRGS mouse).

• They took a mouse that had no immune system of its own.
• They injected it with human immune cells (specifically CD34+ cells).
• They also gave these mice human cancer tumors.

Now, they had a mouse with a human immune system fighting a human tumor. This allowed them to see what happens when human drugs meet human immune cells in a living body.

The Experiment: Pressing the Gas Pedal

The scientists split these special mice into two groups:

1. The Control Group: Got a harmless saltwater injection (the "brakes" stayed on).
2. The Treatment Group: Got the cancer drugs Nivolumab and Ipilimumab (the "brakes" were cut).

They watched what happened to the kidneys over four weeks.

The Findings: What Went Wrong?

When the scientists looked at the kidneys of the mice that got the drugs, they found trouble, but only in the mice with human immune cells. The regular mice were fine.

Here is what they discovered inside the damaged kidneys:

• The Wrong Crowd Arrived: The kidney became crowded with a specific type of human security guard called CD4+ T-cells. Think of these as the "instigators" who were shouting louder and causing more trouble than the other guards (CD8+ cells).
• The Chemical Storm: The damaged kidneys were flooded with angry chemical signals (cytokines and chemokines). It was like a riot where everyone was screaming at once.
• Specific Culprits: The scientists found high levels of "weapons" like Granzyme A/B (which punch holes in cells) and a protein called NGF-beta. At the same time, a "peacekeeper" protein called IL-4 went down.
• The Damage: The kidneys showed signs of vasculitis (inflammation of the blood vessels) and interstitial nephritis (swelling in the tissue between the kidney tubes).

The Clues (Biomarkers)

Usually, doctors look for specific "smoke signals" (biomarkers) to know if a kidney is hurt. In this study, the usual smoke signals (like KIM-1 and NGAL) didn't show up. They were silent.

However, the scientists found new clues:

• The amount of PD-1 and MIF (proteins that act like flags) in the kidney tissue matched the amount of damage.
• The levels of CCL1, IL-15, and BAFF were linked to the blood vessel inflammation.
• There was a slight drop in EGF, a protein that helps repair tissue.

The Conclusion

The main takeaway is that this special mouse model works like a perfect simulation. It showed that when you give these cancer drugs to a system with human immune cells, it triggers a specific chain reaction:

1. Certain human T-cells take over.
2. They release a specific mix of angry chemicals.
3. This causes the kidney to get inflamed and damaged.

The paper concludes that this mouse setup is a validated testing ground. It proves that by watching these specific human immune cells and chemical signals, scientists can understand how the drugs hurt the kidneys and potentially find new ways to stop that damage while keeping the cancer-fighting power alive.

Technical Summary

Technical Summary: Nephrotoxicity of Immune Checkpoint Inhibitors in Mice with a Human Immune System

Problem Statement
Immune checkpoint inhibitors (ICIs), such as those targeting PD-1 and CTLA-4, are established therapies that enhance antitumor responses by blocking inhibitory receptors. However, their mechanism of action carries a risk of systemic toxicity resembling autoimmune diseases, including specific kidney manifestations. While the clinical challenge of ICI-induced nephrotoxicity is recognized, there is a need for preclinical models that can accurately profile immune signaling and interrogate the specific mechanisms driving this renal injury in a human-relevant context.

Methodology
The study utilized a Human Immune System (HIS) tumor-bearing mouse model to investigate the effects of combination ICI therapy (nivolumab and ipilimumab).

• Model Generation: Immunodeficient BRGS (BALB/c-Rag2nullIl2r{gamma}nullSirpNOD) neonates were engrafted with human CD34+ cells to generate HIS-BRGS mice.
• Tumor Implantation: Human MDA-MB-231 tumor cells were implanted subcutaneously. Treatment commenced once tumors reached approximately 150 mm³.
• Experimental Groups: Mice were divided into four cohorts: Vehicle-treated BRGS (n=4), ICI-treated BRGS (n=6), Vehicle-treated HIS-BRGS (n=7), and ICI-treated HIS-BRGS (n=7).
• Intervention: Mice received weekly intraperitoneal injections of either vehicle (PBS) or ICI (nivolumab 20 mg/kg + ipilimumab 10 mg/kg) for 4 weeks.
• Analytical Techniques: Kidney tissues were assessed via histopathology (H&E, TEM), flow cytometry for human immune phenotyping, multiplex ELISA (measuring 80 human proteins and 10 injury biomarkers), bulk RNA sequencing, and targeted qPCR. Pearson correlations were employed to identify predictors of histopathological injury.

Key Results

• Histopathology: Renal vasculitis and interstitial nephritis were observed exclusively in the ICI-treated HIS-BRGS mice, indicating that the presence of a human immune system is requisite for modeling this specific toxicity.
• Immune Profiling: The injured kidneys exhibited a shift toward CD4+ T-cell enrichment with an increased capacity for TNF production compared to CD8+ counterparts.
• Molecular Signatures:
  • Toxicity was associated with elevated renal concentrations of human cytokines, chemokines, and soluble receptors.
  • ICI treatment significantly increased serine proteases (Granzyme A/B) and NGF-{beta}, while decreasing IL-4.
  • Interstitial nephritis correlated with renal PD-1 and MIF.
  • Renal vasculitis correlated with kidney PD-1, CCL1, MIF, Granzyme A, IL-15, and BAFF.
• Biomarker Analysis: Traditional injury biomarkers (KIM-1, NGAL) remained unchanged. However, a trending decrease in EGF was observed.

Significance and Claims
The paper posits that shifts in human T-cell populations and specific immune proteins serve as promising biomarkers and mechanistic targets for understanding ICI nephrotoxicity. The authors claim that the tumor-bearing HIS-BRGS mouse model reproducibly recapitulates the histopathological and immunological features of human ICI-induced nephrotoxicity. Consequently, this model is presented as a validated preclinical platform suitable for testing novel therapeutic interventions aimed at preserving kidney function during cancer immunotherapy.